Drug Type Universal CAR-T |
Synonyms Allogeneic cell therapy product consisting of genetically modified V(delta)2 T cells that express an anti-B7-H3 CAR and membrane-bound IL-15 |
Target |
Action inhibitors |
Mechanism CD276 inhibitors(CD276 antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Malignant glioma of brain | Preclinical | United States | 19 Mar 2025 |